Home › Companies › ORIC PHARMACEUTICALS INC. › 2023-2024
At ORIC PHARMACEUTICALS INC.'s shareholder meeting held June 12, 2024, in the 2023-2024 proxy season, 50 asset managers reported how they voted on 3 ballot items in their SEC Form N-PX filings, covering 443 separate fund positions. On the most widely held item on that ballot — Election of Directors: Lori Kunkel, M.D. — ORIC PHARMACEUTICALS INC.'s filing reports the nominee as elected, with 99% support of the votes cast (FOR divided by FOR plus WITHHELD, because this ballot offered only for and withhold; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: ORIC PHARMACEUTICALS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 14, 2024.
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and ORIC PHARMACEUTICALS INC.’s Form 8-K, filed June 14, 2024 (Item 5.07 on EDGAR). Page generated November 8, 2026.
Meeting of June 12, 2024: 3 items on ORIC PHARMACEUTICALS INC.’s Form 8-K, filed June 14, 2024: 2 elected · 1 approved.
Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided
Proxy season: 2023-2024 2025-2026
Explore ORIC PHARMACEUTICALS INC. in the interactive database Compare manager voting policies
These tallies are ORIC PHARMACEUTICALS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 14, 2024 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Richard Heyman, Ph.D. | 36,581,862 | -- | -- | 11,942,627 | 7,452,621 | 75% | Elected | — |
| Elect Director: Lori Kunkel, M.D. | 48,020,921 | -- | -- | 509,099 | 7,447,090 | 99% | Elected | — |
| 2. Ratification of Appointment of Independent Registered Public Accounting Firm The appointment of KPMG LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024 | 55,632,738 | 6,150 | 338,222 | -- | 0 | 99.9% | Approved | — |
Source: ORIC PHARMACEUTICALS INC., Form 8-K, filed with the SEC on June 14, 2024 — read the filing on EDGAR.
Each item below shows how the 50 asset managers that disclosed a ORIC PHARMACEUTICALS INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 3 wordings of this item as funds reported it.
99% Majority: yes · of votes cast
Description as filed by funds: Election of Directors: Lori Kunkel, M.D.
ORIC PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Lori Kunkel, M.D.”): 48,020,921 for, 509,099 withheld, per its Form 8-K filed June 14, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Each of the following nominees was elected to serve as a Class I director, to hold office until the Company's 2027 annual meeting of stockholders or until his or her respective successor has been duly elected and qualified or his or her earlier resignation or removal.”
Support: 99% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 49 asset managers below reported 10,420,067 for, 124,351 withheld.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 2,698,875 | 0 | 0 | 0 | For |
| Fidelity | 1,468,896 | 0 | 0 | 0 | For |
| BlackRock | 1,294,710 | 0 | 0 | 0 | For |
| T. Rowe Price | 1,222,782 | 0 | 0 | 0 | For |
| MERIDIAN FUND INC | 677,161 | 0 | 0 | 0 | For |
| Advantage Advisers Xanthus Fund, L.L.C. | 531,690 | 0 | 0 | 0 | For |
| State Street | 512,868 | 0 | 0 | 0 | For |
| Invesco | 413,219 | 0 | 0 | 0 | For |
| Victory Capital | 323,042 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 234,001 | 0 | 0 | 0 | For |
| Dimensional | 0 | 0 | 0 | 112,848 | Withhold |
| Charles Schwab | 104,544 | 0 | 0 | 0 | For |
| Equitable | 102,199 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 88,615 | 0 | 0 | 0 | For |
| SEI | 85,735 | 0 | 0 | 0 | For |
| ALGER FUNDS | 83,393 | 0 | 0 | 0 | For |
| TIAA | 80,109 | 0 | 0 | 0 | For |
| John Hancock | 59,765 | 0 | 0 | 0 | For |
| Lincoln Financial | 51,424 | 0 | 0 | 1,829 | For |
| American Century | 47,900 | 0 | 0 | 0 | For |
| ALGER PORTFOLIOS | 42,179 | 0 | 0 | 0 | For |
| Advisors' Inner Circle Fund III | 39,807 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 35,655 | 0 | 0 | 0 | For |
| ALGER INSTITUTIONAL FUNDS | 31,902 | 0 | 0 | 0 | For |
| ProShares | 26,887 | 0 | 0 | 0 | For |
Showing the 25 largest of 49 asset managers. All 49 are in the interactive database (link above).
Combines 3 wordings of this item as funds reported it.
75% Majority: yes · of votes cast
Description as filed by funds: Election of Directors: Richard Heyman, Ph.D.
ORIC PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Richard Heyman, Ph.D.”): 36,581,862 for, 11,942,627 withheld, per its Form 8-K filed June 14, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Each of the following nominees was elected to serve as a Class I director, to hold office until the Company's 2027 annual meeting of stockholders or until his or her respective successor has been duly elected and qualified or his or her earlier resignation or removal.”
Support: 75% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 49 asset managers below reported 8,669,413 for, 1,875,005 withheld.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 2,698,875 | 0 | 0 | 0 | For |
| Fidelity | 1,468,896 | 0 | 0 | 0 | For |
| BlackRock | 1,294,710 | 0 | 0 | 0 | For |
| T. Rowe Price | 1,222,782 | 0 | 0 | 0 | For |
| MERIDIAN FUND INC | 677,161 | 0 | 0 | 0 | For |
| Advantage Advisers Xanthus Fund, L.L.C. | 0 | 0 | 0 | 531,690 | Withhold |
| State Street | 512,136 | 0 | 0 | 732 | For |
| Invesco | 0 | 0 | 0 | 413,219 | Withhold |
| Victory Capital | 0 | 0 | 0 | 323,042 | Withhold |
| FRANKLIN STRATEGIC SERIES | 234,001 | 0 | 0 | 0 | For |
| Dimensional | 0 | 0 | 0 | 112,848 | Withhold |
| Charles Schwab | 104,544 | 0 | 0 | 0 | For |
| Equitable | 72,039 | 0 | 0 | 30,160 | Mixed |
| Direxion Shares ETF Trust | 0 | 0 | 0 | 88,615 | Withhold |
| SEI | 85,735 | 0 | 0 | 0 | For |
| ALGER FUNDS | 0 | 0 | 0 | 83,393 | Withhold |
| TIAA | 80,109 | 0 | 0 | 0 | For |
| John Hancock | 44,984 | 0 | 0 | 14,781 | Mixed |
| Lincoln Financial | 33,500 | 0 | 0 | 19,753 | Mixed |
| American Century | 0 | 0 | 0 | 47,900 | Withhold |
| ALGER PORTFOLIOS | 0 | 0 | 0 | 42,179 | Withhold |
| Advisors' Inner Circle Fund III | 39,711 | 0 | 0 | 96 | For |
| QUANTITATIVE MASTER SERIES LLC | 35,655 | 0 | 0 | 0 | For |
| ALGER INSTITUTIONAL FUNDS | 0 | 0 | 0 | 31,902 | Withhold |
| ProShares | 0 | 0 | 0 | 26,887 | Withhold |
Showing the 25 largest of 49 asset managers. All 49 are in the interactive database (link above).
Combines 2 wordings of this item as funds reported it.
99.9% Approved · of votes cast
Description as filed by funds: RATIFY THE APPOINTMENT OF KPMG LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR OUR FISCAL YEAR ENDING DECEMBER 31, 2024.
ORIC PHARMACEUTICALS INC.’s own tally for this item (“2. Ratification of Appointment of Independent Registered Public Accounting Firm The appointment of KPMG LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024”): 55,632,738 for, 6,150 against — passed, per its Form 8-K filed June 14, 2024 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Proposal 2 - Ratification of Appointment of Independent Registered Public Accounting Firm The appointment of KPMG LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024 was ratified based on the following results of voting:”
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 49 asset managers below reported 10,544,418 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 2,698,875 | 0 | 0 | 0 | For |
| Fidelity | 1,468,896 | 0 | 0 | 0 | For |
| BlackRock | 1,294,710 | 0 | 0 | 0 | For |
| T. Rowe Price | 1,222,782 | 0 | 0 | 0 | For |
| MERIDIAN FUND INC | 677,161 | 0 | 0 | 0 | For |
| Advantage Advisers Xanthus Fund, L.L.C. | 531,690 | 0 | 0 | 0 | For |
| State Street | 512,868 | 0 | 0 | 0 | For |
| Invesco | 413,219 | 0 | 0 | 0 | For |
| Victory Capital | 323,042 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 234,001 | 0 | 0 | 0 | For |
| Dimensional | 112,848 | 0 | 0 | 0 | For |
| Charles Schwab | 104,544 | 0 | 0 | 0 | For |
| Equitable | 102,199 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 88,615 | 0 | 0 | 0 | For |
| SEI | 85,735 | 0 | 0 | 0 | For |
| ALGER FUNDS | 83,393 | 0 | 0 | 0 | For |
| TIAA | 80,109 | 0 | 0 | 0 | For |
| John Hancock | 59,765 | 0 | 0 | 0 | For |
| Lincoln Financial | 53,253 | 0 | 0 | 0 | For |
| American Century | 47,900 | 0 | 0 | 0 | For |
| ALGER PORTFOLIOS | 42,179 | 0 | 0 | 0 | For |
| Advisors' Inner Circle Fund III | 39,807 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 35,655 | 0 | 0 | 0 | For |
| ALGER INSTITUTIONAL FUNDS | 31,902 | 0 | 0 | 0 | For |
| ProShares | 26,887 | 0 | 0 | 0 | For |
Showing the 25 largest of 49 asset managers. All 49 are in the interactive database (link above).
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 67,422,307 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Vanguard | 4.00% |
| 2 | Fidelity | 2.18% |
| 3 | BlackRock | 1.92% |
| 4 | T. Rowe Price | 1.81% |
| 5 | MERIDIAN FUND INC | 1.00% |
| 6 | Advantage Advisers Xanthus Fund, L.L.C. | 0.79% |
| 7 | State Street | 0.76% |
| 8 | Invesco | 0.61% |
| 9 | Victory Capital | 0.48% |
| 10 | FRANKLIN STRATEGIC SERIES | 0.35% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row names its form.
| Holder | % outstanding | Disclosure |
|---|---|---|
| Venrock Healthcare Capital Partners III, L.P. | 9.78% | 13G |
| VIKING GLOBAL INVESTORS LP | 9.75% | 13G |
| Entities affiliated with EcoR1 Capital, LLC | 9.31% | DEF14A |
| Pfizer Inc. | 7.97% | DEF14A |
| Entities affiliated with Nextech Crossover LP | 7.84% | DEF14A |
| Nextech Crossover I SCSp | 7.84% | 13G |
| BlackRock | 7.83% | 13F |
| Entities affiliated with FMR LLC | 7.56% | DEF14A |
| Vanguard Group | 6.90% | 13F |
| SR One Capital Management, LLC | 6.85% | 13D |
Percentages above are of 67,422,307 shares outstanding, as reported by ORIC PHARMACEUTICALS INC. on its Form 10-Q dated April 26, 2024 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from ORIC PHARMACEUTICALS INC.’s 10-Q dated April 26, 2024. This page is a static snapshot rebuilt weekly on November 8, 2026; a live search always shows the current data.
ORIC PHARMACEUTICALS INC. proxy season coverage: 2023-2024 (this page) · 2025-2026.
proxyvotesnow.com, “ORIC PHARMACEUTICALS (ORIC) 2024 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/oric-pharmaceuticals-inc/2024 (version of November 8, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.